Gene ID |
2056 |
Accession | P01588 |
Alternative Name | Erythropoietin<br/>Recombinant Human Erythropoietin-Alpha (EPO) |
Species | Human |
Source | CHO |
Description | EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation. |
Accession | P01588 |
Functions | Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be less than 0.2ng/ml |
Formulation | Lyophilized from a 0.2 ?m filtered solution in PBS (pH 7) |
Solubility | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. |
Appearance | Lyophilized Powder |
Molecular Weight | 20 |
Purity | >95% as determined by SDS-PAGE |
Concentration | <1.0 EU/μg of recombinant protein as determined by the LAL method |
Shipping Condition | Ambient Temperature |
Storage Condition | The lyophilized protein is stable for at least one year from date of receipt at -70?C. Upon reconstitution, this cytokine can be stored in working aliquots at 2? - 8?C for one month, or at -20?C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. |